Skip to main content
Fig. 4 | Cost Effectiveness and Resource Allocation

Fig. 4

From: Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia

Fig. 4

Top five most influential factors identified in one-way sensitivity analysis for the cost-effectiveness of PHiD-CV 2+1 versus PCV13 2+1. AOM acute otitis media, PHiD-CV pneumococcal polysaccharide and NTHi protein D conjugate vaccine, ST19A serotype 19A, IPD invasive pneumococcal disease, GP general practitioner, PCV13 13-valent pneumococcal conjugate vaccine, ST6B serotype 6B, USD United States dollars

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us